RP-3 by Replimune for Gastrointestinal Tract Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Gastrointestinal Tract Cancer.

New registry offers insights into quality of life for adults with congenital heart disease

For the first time, adults living with congenital heart disease (CHD) now have valuable insights into their long-term quality of life through data from the

October 16, 2024

Merck, Kelun trumpet Phase 3 breast cancer data for anti-TROP2 ADC

Merck and Kelun-Biotech revealed Phase 3 breast cancer data for the lead antibody-drug conjugate in their potentially $12 billion partnership. In a Phase 3 trial

May 24, 2024

MSD’s Keytruda use in adenocarcinoma could be limited based on biomarker – Pharmaceutical Technology

MSD will now work with the FDA to update Keytruda’s label. Source: Shutterstock / Atmosphere1. Merck (MSD) has announced updated results with Keytruda (pembrolizumab) in

June 16, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.